OBJECTIVES: Recently, the need for health services has increased gradually and the limitations in sources allocated for this area have been recognized. Moving from this fact, it has gained a supreme importance to determine what health programs or technologies will be given priority. According to Danzon (2001), arrangements towards controlling the expenses through price and profit controls, reimbursement methods and incentives have recently gained wide currency METHODS: This present study examines; along with the current situation in Turkey, pharmaceutical pricing methods, reimbursement methods and basic health indicators, within the scope of changing pharmaceutical policies, in Turkey, obtained results and effects of those results so far. RESULTS: Upon the research conducted, it was founded that the pharmaceutical policies in Turkey has been effected medicines prices dramatically last few years. Pricing and Reimbursement regulation changed several times and but public health expenditure hasn’t decreased. Access to healthcare was main factor of health expenditures. Rational drug use was another issue which is main aim to Turkish Authorities CONCLUSIONS: Although it is natural for Turkey to put restrictions on drugs budget to ensure sustainable drug financing, in order to maintain the existence of pharmaceutical industry and protect the patients’ access to medicines; it would be more favorable in the development of the industry that the expectations of the stakeholders in the industry are taken into account in the policy making process. This would also help the already supported R&D activities to be sustainable as well. The positive and negative aspects of Turkey’s offering the least expensive medicine should be examined. Whether being the country to supply the least expensive medicine is the correct objective or not in the international arena should seriously be discussed. It is recommended that how this situation affects Turkey’s image in the outer world should be scrutinized.